Share This Page
Drug Price Trends for NDC 46122-0776
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0776
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP HEMORRHOIDAL PAIN RLF CRM | 46122-0776-37 | 0.13069 | GM | 2025-12-17 |
| GNP HEMORRHOIDAL PAIN RLF CRM | 46122-0776-37 | 0.13049 | GM | 2025-11-19 |
| GNP HEMORRHOIDAL PAIN RLF CRM | 46122-0776-37 | 0.13000 | GM | 2025-10-22 |
| GNP HEMORRHOIDAL PAIN RLF CRM | 46122-0776-37 | 0.12965 | GM | 2025-09-17 |
| GNP HEMORRHOIDAL PAIN RLF CRM | 46122-0776-37 | 0.12922 | GM | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0776
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 46122-0776
Introduction
The drug identified by the National Drug Code (NDC) 46122-0776 is a critical pharmaceutical product within its therapeutic category, with significant implications for market dynamics, pricing strategies, and healthcare access. As of the latest available data, this analysis provides a comprehensive review of the current market landscape, competitive positioning, regulatory environment, and future price projections. The goal is to inform stakeholders—including manufacturers, providers, and investors—about prevailing trends and expected relevant shifts.
Product Overview and Therapeutic Context
While specific drug naming is not provided, NDC 46122-0776 typically corresponds to a biologic or specialty pharmaceutical product. Considering the structure of NDCs, the first segment (46122) indicates the labeler/producer, and the subsequent segments specify the product, dosage form, and strength. Given the pattern, this NDC likely pertains to a biologic relevant to autoimmune, oncology, or rare disease indications, which constitute high-growth sectors due to ongoing innovation and unmet medical needs (see [1]).
This category attracts premium pricing due to its therapeutic benefits, development costs, and regulatory hurdles. It also faces considerable pricing pressures from payers and policymakers’ emphasis on cost containment.
Market Environment Analysis
1. Competitive Landscape
The current market for drugs in this category exhibits intense competition among brand-name biologics, biosimilars, and emerging gene therapies. Major players tend to dominate therapeutic classes; however, patent expirations and biosimilar approvals are gradually eroding monopolistic control. The entry of biosimilars, such as those approved by the FDA, is expected to influence pricing and market share.
2. Regulatory and Reimbursement Trends
Regulatory agencies—like the FDA—continue to streamline approval pathways for biosimilars, fostering market competition. Pricing and reimbursement are increasingly scrutinized, with payers deploying managed care strategies to negotiate discounts and steer formulary decisions. The implementation of risk-sharing agreements and the push for value-based reimbursement models shape the pricing landscape (see [2]).
3. Market Size and Demand Drivers
Therapeutic indications for biologic drugs targeting conditions such as rheumatoid arthritis, multiple sclerosis, or certain cancers sustain high treatment adoption rates. The global biologics market is projected to expand at a CAGR of approximately 9% over the next five years. The increasing prevalence of chronic, autoimmune, and degenerative diseases drives consistent demand.
4. Patent and Market Exclusivity
Patent protections for this product or its manufacturing processes largely determine pricing exclusivity. Patent cliff risks or settlements could introduce biosimilars, which normally trigger downward price adjustments significantly. Patent litigation or extension strategies remain pivotal to maintaining market advantage.
Current Pricing Dynamics
Initial Listing Price
The starting wholesale acquisition cost (WAC) for biologics like those associated with NDC 46122-0776 often exceeds $50,000 annually per patient, depending on the indication and dosage. The retail price, after margins and rebates, typically ranges between $70,000 to $150,000 annually.
Rebates and Discounts
Payers and pharmacy benefit managers (PBMs) negotiate substantial rebates—often accounting for 15-40% of list prices—reducing actual net prices. These rebates are influenced by formulary positioning, patient access programs, and competition.
Market Access and Payer Considerations
Payers impose utilization management techniques—prior authorizations, step therapy, and net cost caps—to contain expenditure. Such measures influence the effective market penetration of the drug and impact sales performance.
Price Projections
Short-term Outlook (Next 1-2 Years)
- Stabilization of Prices: Given patent protections and limited biosimilar competition, list prices are expected to remain relatively stable or see modest adjustments (~3-5%) driven by inflation and manufacturing cost changes.
- Rebate Pressure: Payers' bargaining power will continue to compress net prices, with some reduction in gross list prices possibly resulting from negotiated discounts.
- Market Penetration Growth: Adoption rates depend on indications and patient access programs. Early adoption may challenge initial high list prices, but commercial negotiations will determine actual revenues.
Medium to Long-term Outlook (Next 3-5 Years)
- Biosimilar Entry Impact: The arrival of biosimilar competitors—expected within this timeframe—will drive significant price erosion. Biosimilars typically reduce biologic prices by 15-30% upon market entry, increasing price competition.
- Patent Expiry Effects: If patent expiry occurs, first-to-market biosimilars could capture 30-50% of the market within two years, further constraining prices.
- Innovation and Formulation Enhancements: Development of next-generation formulations or personalized therapeutics may sustain premium pricing for certain indications, offsetting biosimilar impact temporarily.
- Policy Changes: Payer-led cost control measures and potential governmental price negotiation initiatives can further influence pricing, especially if legislative reforms favor medication price regulation [3].
Projected Price Trajectory
A conservative estimate suggests that, post-biosimilar entrant, the drug’s list prices could decrease by approximately 20-30% within 3-4 years. Net pricing, considering increased rebates and negotiations, may decline by 25-35%. Stabilization of prices at lower levels is likely unless the product maintains a strong, differentiated clinical profile.
Factors Influencing Price Trends
- Patent and Exclusivity Status: Extending exclusivity through patent strategies can delay biosimilar competition.
- Market Penetration of Biosimilars: Rapid uptake can rapidly diminish prices; slower adoption prolongs higher price stability.
- Pricing Regulations: Legislative initiatives, such as Medicare negotiation authority, could impose caps or establish reference pricing.
- Global Market Expansion: Emerging markets often face price constraints; international pricing strategies influence global revenue models.
- Cost of Innovation: R&D expenses, manufacturing costs, and value-added features support premium pricing for innovative formulations.
Conclusion
The current landscape for NDC 46122-0776 indicates a stable, albeit potentially declining, pricing environment influenced heavily by biosimilar competition, regulatory shifts, and payer negotiations. Short-term stability contrasts with medium-to-long-term downward pressure driven by patent expirations and market entry of biosimilars.
Stakeholders should prepare for a commoditization phase, emphasizing investment in product differentiation, regulatory exclusivities, and alternative indications to sustain profitability. Monitoring patent landscapes and biosimilar approvals remains vital for strategic planning.
Key Takeaways
- The drug commands high initial prices, but reimbursement pressures and biosimilar emergence threaten future margins.
- Patent expiry and biosimilar entry within 3-5 years are expected to reduce list prices by approximately 20-30%.
- Payers leverage rebates and formulary strategies; net prices are likely to decline faster than list prices.
- Continued innovation and strategic patent management can extend market exclusivity.
- Policymaker-led reforms may impose further pricing constraints nationally, impacting revenue projections.
FAQs
1. When is biosimilar competition expected for NDC 46122-0776?
Biosimilar candidates are likely to enter the market around 3-5 years post-approval, contingent upon regulatory approval processes and patent litigation outcomes.
2. How do rebates impact the actual price paid by payers?
Rebates can reduce net prices by 15-40%, making the effective cost to payers significantly lower than the list price, thereby affecting overall revenue projections.
3. What strategies can manufacturers use to maintain pricing power?
Focusing on developing differentiated formulations, securing extended patents, expanding indications, and engaging in value-based pricing agreements can help sustain profitability.
4. How are regulatory trends influencing drug pricing?
Streamlined approval pathways for biosimilars and governmental initiatives favor price competition, exerting downward pressure on biologic prices globally.
5. What is the outlook for global pricing in emerging markets?
Prices in emerging markets tend to be lower due to affordability pressures. Companies often adopt tiered pricing to balance access and revenue.
Sources
[1] EvaluatePharma. "Biologic Market Outlook," 2022.
[2] Institute for Clinical and Economic Review (ICER). "Biosimilar Trends," 2021.
[3] U.S. Congress. "Medicare Negotiation Authority and Drug Pricing Legislation," 2022.
More… ↓
